HomeLSTA • NASDAQ
add
Lisata Therapeutics Inc
Previous close
$2.82
Day range
$2.86 - $2.94
Year range
$2.05 - $3.83
Market cap
23.99M USD
Avg Volume
15.39K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 5.34M | -10.53% |
Net income | -4.93M | 6.29% |
Net profit margin | — | — |
Earnings per share | -0.59 | 9.23% |
EBITDA | -5.29M | 10.53% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 35.86M | -34.08% |
Total assets | 38.20M | -34.24% |
Total liabilities | 4.76M | -11.55% |
Total equity | 33.44M | — |
Shares outstanding | 8.39M | — |
Price to book | 0.70 | — |
Return on assets | -33.03% | — |
Return on capital | -37.23% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -4.93M | 6.29% |
Cash from operations | -2.52M | 29.72% |
Cash from investing | -6.30M | -151.46% |
Cash from financing | 0.00 | 100.00% |
Net change in cash | -8.78M | -200.53% |
Free cash flow | -1.00M | 39.01% |
About
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through the acquisition of Cend Therapeutics by Caladrius Biosciences in September 2022.
In April 2024 the FDA granted their product, certepetide, orphan drug status. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
Founded
1980
Headquarters
Website
Employees
25
